Pharmacy-Based Methadone: A New Lifeline in the Fight Against the Opioid Crisis
A recent study led by University of Rhode Island Clinical Professor of Pharmacy Jeffrey Bratberg reveals a promising path forward in addressing the opioid crisis: expanding access to methadone through pharmacies. Published in JAMA Network Open, the research demonstrates the financial viability of pharmacy-based methadone dispensing, potentially revolutionizing treatment access for individuals struggling with opioid use disorder.
The Current Landscape of Opioid Treatment
Despite a 26% decrease in overdose deaths between 2023 and 2024, a significant number of individuals remain untreated for opioid use disorder. Traditional opioid treatment programs (OTPs) often face limitations in capacity and geographic accessibility, creating barriers to care. This study explores alternative models to bridge these gaps.
Two Models for Pharmacy-Based Methadone Dispensing
Researchers evaluated two distinct models for dispensing methadone within a pharmacy setting. The first, a “pharmacist-dispensed” model, involves medical professionals prescribing methadone directly to patients, with pharmacists handling the dispensing. This model showed a potential return of $2.64 for every dollar spent, translating to a net profit of $23,844 over three years.
The second, a “medication unit” model, leverages existing OTP clinicians to prescribe methadone, even as pharmacists manage the dispensing process. This approach proved even more financially attractive, with an estimated return of $3.53 per dollar spent and a net profit of $96,904 over three years. This model is currently permissible under existing regulations.
Financial Sustainability: A Key to Long-Term Access
Bratberg emphasizes the importance of financial viability, stating, “It is a disservice to your patient if you start something and later say ‘I can’t keep doing this because it’s not financially viable.’” The study highlights that pharmacies, often operating on tight margins, necessitate sustainable models to ensure continued access to essential medications. A pharmacy’s closure means a loss of access to *all* medications for patients, a risk this research aims to mitigate.
Regulatory Hurdles and the Path to Change
While the medication unit model is currently legal, the pharmacist-dispensed model requires a shift in the U.S. Drug Enforcement Administration’s (DEA) regulatory interpretation. Bratberg believes the ingredients for change are already in place. “Patients want it. Pharmacists are trained to do it. Pharmacies exist where patients want it. And now we know this is something that is also feasible and sustainable from a profit and loss perspective,” he explains. A regulatory adjustment could unlock a significant expansion of life-saving treatment options.
Future Trends: Expanding Access and Integrated Care
This research signals a broader trend toward integrating substance use disorder treatment into mainstream healthcare settings. Expect to see:
Increased Pharmacist Involvement
Pharmacists are increasingly recognized as vital members of the healthcare team, capable of providing comprehensive medication management and addiction care. Further training and expanded prescribing authority could empower pharmacists to play an even greater role.
Telehealth Integration
Telehealth offers a promising avenue for expanding access to methadone treatment, particularly in rural or underserved areas. Remote prescribing and monitoring could overcome geographic barriers and improve patient convenience.
Harm Reduction Strategies
Pharmacy-based methadone dispensing aligns with broader harm reduction strategies, such as naloxone distribution and syringe exchange programs. These approaches prioritize keeping people alive and engaged in care, ultimately reducing overdose deaths.
FAQ
Q: Is methadone dispensing in pharmacies currently legal?
A: The medication unit model is currently legal. The pharmacist-dispensed model requires a change in DEA regulations.
Q: What are the benefits of pharmacy-based methadone dispensing?
A: Increased access to treatment, improved financial sustainability for pharmacies and greater convenience for patients.
Q: What role did Jeffrey Bratberg play in this research?
A: Professor Bratberg, the sole pharmacist author, contributed his expertise in addiction care and community pharmacy research to the study.
Q: What is the Opioid Policy Research Collaborative?
A: It is a collaborative at Brandeis University dedicated to finding ways to increase access to care for underserved people in the nation.
Did you know? The study found that pharmacies utilizing the medication unit model could see a net profit of over $96,000 over three years.
Pro Tip: Advocate for policies that support expanded access to medication-assisted treatment in your community.
Learn more about the research here.
What are your thoughts on expanding access to methadone through pharmacies? Share your comments below!
